Coming of Age

Helping adolescent patients – and their doctors – smooth the transition from pediatric to adult care

Learn more

The Decline and Fall of Cytotoxic Chemo

In Editor's Corner, Keith Stewart gives his take on whether cytotoxic chemotherapy should be declared a thing of the past.

Learn more

ASH Meeting on Hematologic Malignancies

Read the latest updates from the ASH Meeting on Hematologic Malignancies

Learn more

Written in Blood

Finding a clinical, molecular risk model that predicts disease progression in follicular lymphoma

Learn more

Pulling Back the Curtain

Laura Michaelis talks winding career paths and the similarities between reporting and practicing medicine.

Learn more

New Exclusive Videos

View all Exclusive Videos

  • The Decline and Fall of Cytotoxic Chemotherapy

    Here, Dr. Stewart gives his take on whether cytotoxic chemotherapy should be declared a thing of the past. As ward rounds ended last Saturday, a slow-brew blend of my own clinical experience and what I have seen as reproducibly disappointing outcomes welled inside me to create my strong desire to relegate cytotoxic chemotherapy to the […]

  • Conflict of Conscience

    On the first Wednesday of every month, the Innovation Management and Conflict of Interest Committee at Cleveland Clinic meets to discuss some of the thornier issues that have arisen with our staff members and their relationships with external entities. I am a standing member of this committee, and the majority of our discussions center on […]

  • Magical Thinking

    Okay, I confess. I exhibit magical thinking. I believe in jinxes, in woo woo, and in all of the medical lore and superstitions I learned as a resident. My superstitions are limited to the realm of medicine, though. I don’t care when Friday the 13th rolls around, or when black cats cross my path, or […]

  • Recommendations from My Bookshelf: Cutting for Stone by Abraham Verghese

    Have you ever been a stranger in a strange land? I thought I was when I moved from New England to Cleveland, where I had to learn to talk a little slower, and that unfamiliar people who smiled and said “hi” as they passed me in the hallways were not mentally unstable – as I […]

View all Editor`s Corner
  • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

    Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of […]

  • Optimal Timing of Transplant in Myeloma

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

  • Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

    Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these devices is unclear. The potential complications associated with filter placement and retrieval may outweigh the benefit, particularly in the era of novel oral anticoagulants. ASH Clinical News invited Joseph M. Stavas, […]

  • For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

    Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen for treating acute thrombotic events in these patients, questions remain about its optimal use, including the duration of anticoagulation. ASH Clinical News invited David A. Garcia, MD, and Agnes Y. Lee, […]

View all Drawing First Blood
  • CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

    In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician reimbursements for prescription drugs.1 According to CMS, the rule will test different physician incentives that would, in theory, encourage the prescription of the most effective drugs and reward positive patient outcomes. […]

  • Choosing Wisely Across the Internal Medicine Spectrum: Which Recommendations Should Hematologists Pay Attention To?

    In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies at the 2015 annual meeting. Choosing Wisely encourages clinicians and patients to engage in conversations to reduce waste and overuse in health care. […]

  • New Medicare Care Choices Model Seeks to Expand Access to Palliative Care

    On July 20, 2015, the Centers for Medicare& Medicaid Services (CMS) announcedthe 141 hospices that have been selected to participate in the new Medicare Care Choices Model (MCCM), a pilot program designed to expand patients’ access to palliative and hospice care.1 The new model provides clinicians, beneficiaries, and their families with greater flexibility in deciding between hospice care and active […]

  • ICD-10: Ready or Not!

    After two one-year reprieves, it’s finally here: The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Nationwide, on October 1, 2015, all health-care business transactions in the United States converted to ICD-10 from the previous version of the ICD (ICD-9). If they did not convert, claims and electronic transactions will be rejected. The ICD-9 […]

View all Practice Update